News

Liquet™ Medical Inc. Receives FDA 510(k) Clearance for the Versus™ Catheter

Liquet Medical Inc., a pioneering medical device company committed to advancing patient care through innovative technologies, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Versus™ Catheter. This innovative medical device is set to enhance the treatment of pulmonary artery blood clots by offering real-time pulmonary artery pressure measurements, empowering clinicians to optimize treatment based on individual patient responses. This novel technology enables a new treatment category called Hemodynamics-Led Thrombolysis (HLT).”

“The Versus Catheter will allow for a more data-centric approach to each individual patient suffering from blood clots in their lungs,” said Luke Wilkins, MD, Interventional Radiologist at UVA Health. “Hemodynamic-led thrombolytic therapy is an opportunity to potentially improve patient outcomes, and we are looking forward to studying this device.”

Key Features and Benefits of the Versus™ Catheter:

  • Real-Time Pulmonary Artery Pressure Monitoring: Provides physicians live data to assess patient hemodynamics before and during therapy to optimize treatment decisions.

  • Dual-Tip Telescoping Catheter: Enables simultaneous treatment of both lungs with a single device, offering access site alternatives to the physician, and improving healthcare efficiency.

  • Flexible Placement: Standard guidewire technique or flow-directed balloon placement.

“FDA 510(k) clearance is a significant milestone for Liquet Medical and enables the commercial release of the Versus Catheter to hospitals and clinics across the U.S. We are thrilled to announce FDA clearance for the Versus™ Catheter, a groundbreaking advancement in the treatment of pulmonary artery blood clots,” said John Schindler, CEO of Liquet Medical. “We believe this innovation has the potential to improve patient outcomes, minimize risks, and reduce healthcare costs.

 

Learn more here.

Recent News

03/31/2025

Allozymes and Bonumose Collaborate to Accelerate Enzyme Innovations for Beneficial Food & Supplement Ingredients

Allozymes, a leader in protein engineering, and Bonumose, a leader in innovative enzyme combinations enabling the production of high-volume, healthy, naturally occurring monosaccharides from commodity feedstocks such as starch and sugar, announce the preliminary results of improvements to key enzymes for Bonumose’s ingredient production process. Bonumose enzyme breakthroughs include unique combinations converting plant-based starch and

03/26/2025

New survey: U.S. biotechs warn tariffs could impede access to cures, stifle innovation

Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. According to the findings, nearly 90% of U.S. biotech companies rely on imported components for at least half of their FDA-approved products — making the supply of medicines for US patients and

03/25/2025

AgroSpheres Named on Both the World’s Top GreenTech Companies 2025 and America’s Top GreenTech Companies 2025 Lists by TIME Magazine

AgroSpheres has been named on both the World’s Top GreenTech Companies 2025 and America’s Top GreenTech Companies 2025 lists. These prestigious awards are presented by TIME and Statista Inc., the leading statistics portal and industry ranking provider. The award lists were announced on March 25th, 2025, and can be viewed on TIME’s website. Statista ranked